AME Publishing Company

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Retrieved on: 
Monday, April 22, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Education, National Cancer Center, MET, D.C, Lung cancer, Woman, PMID, Progression-free survival, Harmonic, Machine learning, AME Publishing Company, ClinicalTrials.gov, Collection, Artificial intelligence, IPhone, Adenocarcinoma, ROS1, Disease, Incidence, Patient, Pemetrexed, TMB, SOC, Neoplasm, Lung, ALK, EGFR, NSCLC, Carboplatin, Overalls, Gene, TK, Pharmaceutical industry

Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).

Key Points: 
  • Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).
  • LCINS are histologically, mutationally, and epidemiologically distinct from smoking-related lung cancers and occur almost exclusively as adenocarcinomas and most commonly in women and individuals of Asian ancestry.
  • Dr. Goto will now lead the trial in Japan, where the incidence of non-small cell lung cancer (NSCLC) in never-smokers is double or more than that of the United States.
  • In addition, LP-300 has been administered in multiple clinical trials to more than 1,000 people and has been generally well tolerated.

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Emory Healthcare, Sepsis, Conference, SAMI, Motivation, Clinical professor, Partnership, Patient, EAA, Mayo Clinic, Mortality, Septic shock, EDEN, University, Spectral, Intensive care unit, Critical care, PMX, AME Publishing Company, TSX, Clinical trial, Nephrology, ICU, FDA, UCLA, Baxter, Marketing, Economics, Hemoperfusion, Pharmaceutical industry

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

BioIVT to Host Symposium and Workshop in Brussels on Advanced In Vitro ADME Methodologies

Retrieved on: 
Tuesday, April 9, 2024
Molecule, AME Publishing Company, Development, Hepatocyte, Application, Travel, Running, Doctor of Philosophy, Senior, University of Oxford, ADME, Drug development, MPS

WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques, a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research. Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT. The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications. Please visit BioIVT's website for registration and additional details here. 

Key Points: 
  • WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques , a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research.
  • Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT.
  • The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications.
  • In addition to being the largest supplier of products for in vitro ADME studies, the company also will discuss the preclinical research services it offers, including designing and implementing in vitro ADME-Tox programs.

World Precision Instruments Partners with TotalLab to Introduce 21 CFR Part 11 into the EVOM Product Line

Retrieved on: 
Wednesday, March 20, 2024
AME Publishing Company, Partnership, Microfluidics, Software, Investment, Drug development, WPI, MPS, Medical device

SARASOTA, Fla., March 20, 2024 /PRNewswire/ -- World Precision Instruments (WPI) is pleased to announce their strategic partnership with TotalLab, paving the way for the integration of 21 CFR Part 11 compliance into its esteemed EVOM family of products.

Key Points: 
  • SARASOTA, Fla., March 20, 2024 /PRNewswire/ -- World Precision Instruments (WPI) is pleased to announce their strategic partnership with TotalLab, paving the way for the integration of 21 CFR Part 11 compliance into its esteemed EVOM family of products.
  • This collaboration marks a significant milestone in WPI's commitment to providing cutting-edge solutions for highly regulated industries, particularly the pharmaceutical market.
  • As part of this partnership, WPI is making substantial investments in both software and hardware capabilities to enhance their product offering.
  • Join WPI at the MPS World Summit and witness how they are revolutionizing precision instrumentation for regulated industries.

APPIS 2024: Healthcare Stakeholders Come Together to Prioritize Action for Better Patient Outcomes in Asia Pacific, Middle East, and Africa

Retrieved on: 
Monday, March 11, 2024
Engagement, Success, Health literacy, AME Publishing Company, Congress, Organization, Face, Health, Health equity, Real, Partnership, Novartis, Patient, Health care, Communication, Cancer, Human, HTR, Summit, GMT, Glomus tumor, Physician, Medical device

The APPIS Innovator Program and APPISx are also key components of APPIS that will bring healthcare stakeholders together throughout the year to drive positive impact for patients.

Key Points: 
  • The APPIS Innovator Program and APPISx are also key components of APPIS that will bring healthcare stakeholders together throughout the year to drive positive impact for patients.
  • The Summit aims to facilitate meaningful partnerships to address barriers to access for patients across Asia Pacific, Middle East, and Africa.
  • This year, the APPIS Summit will feature over 40 speakers, including healthcare experts, patient leaders, policymakers, and health journalists.
  • APPISx promotes country-level engagements by bringing together patient organizations and healthcare stakeholders to catalyze action-oriented solutions that address barriers to healthcare.

Spectral Medical Provides February Tigris Trial Update

Retrieved on: 
Wednesday, February 28, 2024
TSX, AME Publishing Company, Sepsis, Lipopolysaccharide, Randomized controlled trial, Patient, Septic shock, Pharmaceutical industry

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • Robust enrollment activity continues throughout 2024:
    With 57 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial
    Currently 21 Tigris trial sites, with continued progress opening an additional four new, high quality clinical sites
    The Institute for Extracorporeal Life Support (San Antonio, TX) finalized and executed the Tigris clinical trial agreement
    Expect significant site onboarding activity throughout Q1/24, with final training scheduled at three of the remaining four sites

Genpax named 2023 winners of the IET Excellence and Innovation Award for Health Technology

Retrieved on: 
Wednesday, November 29, 2023
WGS, Engineering, Whole genome sequencing, IET, Science, Glasgow Science Centre, The Economist, IPC, Control, Excellence, Infection, AME Publishing Company, Public, Pharmaceutical industry, Health care

LONDON, Nov. 29, 2023 /PRNewswire/ -- Genpax, a life science startup focused on transforming healthcare in detecting, tracing, and mitigating the spread of bacterial pathogens, has been announced as a winner by the IET for their 2023 Excellence and Innovation Awards.

Key Points: 
  • LONDON, Nov. 29, 2023 /PRNewswire/ -- Genpax, a life science startup focused on transforming healthcare in detecting, tracing, and mitigating the spread of bacterial pathogens, has been announced as a winner by the IET for their 2023 Excellence and Innovation Awards.
  • The Awards celebrate the most pioneering engineering and technology innovations across 16 sectors, from energy and sustainability to manufacturing and healthcare.
  • Chosen by a panel of expert judges, Genpax won the Health Technology award for their revolutionary pathogen analysis platform IDEM.
  • Dr Nigel Saunders, Chief Scientific Officer and co-founder, said, "I am delighted that IDEM has been recognised for its innovation.

Genpax named 2023 winners of the IET Excellence and Innovation Award for Health Technology

Retrieved on: 
Wednesday, November 29, 2023
WGS, Engineering, Whole genome sequencing, IET, Science, Glasgow Science Centre, The Economist, IPC, Control, Excellence, Infection, AME Publishing Company, Public, Pharmaceutical industry, Health care

LONDON, Nov. 29, 2023 /PRNewswire/ -- Genpax, a life science startup focused on transforming healthcare in detecting, tracing, and mitigating the spread of bacterial pathogens, has been announced as a winner by the IET for their 2023 Excellence and Innovation Awards.

Key Points: 
  • LONDON, Nov. 29, 2023 /PRNewswire/ -- Genpax, a life science startup focused on transforming healthcare in detecting, tracing, and mitigating the spread of bacterial pathogens, has been announced as a winner by the IET for their 2023 Excellence and Innovation Awards.
  • The Awards celebrate the most pioneering engineering and technology innovations across 16 sectors, from energy and sustainability to manufacturing and healthcare.
  • Chosen by a panel of expert judges, Genpax won the Health Technology award for their revolutionary pathogen analysis platform IDEM.
  • Dr Nigel Saunders, Chief Scientific Officer and co-founder, said, "I am delighted that IDEM has been recognised for its innovation.

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Retrieved on: 
Friday, September 1, 2023
AME Publishing Company, Lead, University, Medivir, Clifton Springs Hospital & Clinic, Cancer, DRS, Reig, Oncology, BCLC, Research, CMO, Cancer Science, Defence Scientific Advisory Council, ECMC, University of Glasgow, Liver cancer, Patient, School, Dr. Evan Alexander Erwin House, Webcast, Hospital, HCC, Lenvatinib, Disease, Pharmaceutical industry, Medical device, Beatson West of Scotland Cancer Centre

The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.

Key Points: 
  • The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.
  • He will be joined by Dr. Maria Reig, Liver Cancer Unit, Hospital Clínic BCLC group, Villarroel, Barcelona, Spain, who will discuss how HCC is different from many other tumor types and its unique treatment challenges.
  • Both Drs are investigators in the phase 1b/2a study with fostrox in combination with Lenvima and will also share their perspectives from the ongoing study.
  • The webcast will be streamed via a link on the website: www.medivir.com/investors/presentations The presentation will be available on Medivir´s website after the webcast.

Microphysiological Systems Conference 2023: A Deep Dive into Technologies & Applications - Innovations in 3D-Culture, Organoids, and Organs-on-Chips fields (Orlando, Florida - July 26-27, 2023)

Retrieved on: 
Tuesday, July 4, 2023
Central Florida, City University of Hong Kong, La Jolla Institute for Immunology, University, Impact, Engineering, Organoid, Associate professor, University of Florida, Electrical engineering, AME Publishing Company, MPS, Organ (biology), Royal Army Medical Corps, Novo Nordisk, University of Central Florida, Integration, Cornell University, Conference, City University, 3D printing, Management, Medical imaging, Chemistry

DUBLIN, July 3, 2023 /PRNewswire/ -- The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 3, 2023 /PRNewswire/ -- The "Microphysiological Systems 2023: A Deep Dive into Technologies & Applications" conference has been added to ResearchAndMarkets.com's offering.
  • Topics to be covered include 3D-cell based screening methods, high content screening, and analysis, the use of model systems, and novel approaches for physiologically-relevant analysis of cell systems as well as building these systems (MPS systems).
  • The host is honored that Professor Mike Shuler, Samuel B. Eckert Professor of Engineering at Cornell University and President of Hesperos will be Chairperson of this Conference.
  • Conference Attendees Receive Full Access to the Co-Located EV Conference for Maximal Networking and Scientific Exchange.